MARKET

ADIL

ADIL

Azora Therapeutics Inc
NASDAQ
4.040
-0.180
-4.27%
After Hours: 3.990 -0.05 -1.24% 16:33 09/28 EDT
OPEN
4.050
PREV CLOSE
4.220
HIGH
4.299
LOW
3.850
VOLUME
47.49K
TURNOVER
--
52 WEEK HIGH
10.75
52 WEEK LOW
1.310
MARKET CAP
10.61M
P/E (TTM)
-0.2438
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ADIL last week (0914-0918)?
Weekly Report · 09/21 10:13
Adial Shareholders Approve Key Proposals, Meeting Adjourned
TipRanks · 09/18 20:51
Adial Pharmaceuticals Amends Agreements to Restore Nasdaq Compliance
TipRanks · 09/16 21:29
Weekly Report: what happened at ADIL last week (0907-0911)?
Weekly Report · 09/14 10:18
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/11 17:06
Weekly Report: what happened at ADIL last week (0831-0904)?
Weekly Report · 09/07 10:11
Weekly Report: what happened at ADIL last week (0824-0828)?
Weekly Report · 08/31 10:18
Adial Pharmaceuticals files to sell 25.15M shares of common stock for holders
TipRanks · 08/28 20:55
More
About ADIL
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.

Webull offers Adial Pharmaceuticals Inc stock information, including NASDAQ: ADIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADIL stock methods without spending real money on the virtual paper trading platform.